Work

1417P Comparative efficacy and safety of tislelizumab versus anti-PD-1 treatments in second-line esophageal squamous cell carcinoma: Simulated treatment comparisons

Year: 2024

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.1483

Authors: E.C. Smyth, J.A. Ajani, K. Wang, J. Coaquira Castro, M. Figueiredo, J-M. Sun, K. Soulanis, A. Tasoulas, G. Nikolaidis, E. Priedane, L. Zhan

Institutions: Churchill Hospital, The University of Texas MD Anderson Cancer Center, Universidade Estadual de Campinas (UNICAMP), Samsung Medical Center, Sungkyunkwan University, IQVIA (United Kingdom)

Language: English

Topic: Esophageal Cancer Research and Treatment

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, American Society of Clinical Oncology, BeiGene, Seagen, Eisai, Astellas Pharma, Daiichi Sankyo Europe

OpenAlex ID: W4402560592

FWCI:

Cites:

Cited by:

Related to: 10